Sunday, June 1, 2025

Latest

Medicago, GSK Report 71% Efficacy Rate From Plant-Based COVID-19 Vaccine Study

Quebec-based biopharmaceutical firm Medicago and healthcare conglomerate GlaxoSmithKline (NYSE: GSK) announce today the results from its global Phase 3 efficacy study of its COVID-19 vaccine candidate. The data showed an overall efficacy rate of 71% against all variants of SARS-CoV-2, the virus that causes the pandemic disease.

The Canadian firm’s plant-based vaccine candidate is combined with GSK’s pandemic adjuvant. The firm is using a unique technology to produce virus-like particles, designed to mimic the virus structure for the immune system to recognize ahead of the potential infection.

The study, started in March 2021, was conducted with over 24,000 subjects ages 18 years old and above across Canada, the United States, the United Kingdom, Mexico, Argentina, and Brazil. The vaccine was administered in two doses of 3.75 µg, 21 days apart.

The vaccine candidate also showed a 75.3% efficacy rate specifically against the Delta variant and 88.6% against the Gamma variant. The emerging Omicron variant has not been considered yet in the study.

During the study, the firm reported no related serious adverse events while reactions to the vaccine were “generally mild to moderate and transient”, with “symptoms lasting on average only 1 to 3 days.”

The biopharmaceutical firm plans to seek regulatory approval from Health Canada as part of its rolling submission. The phase 3 results are also expected to be released in a peer-reviewed publication.


Information for this briefing was found via the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Pfizer-BioNTech COVID-19 Vaccine Trial For Ages 5-11 Returns Favorable Topline Results

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced this morning the topline results...

Monday, September 20, 2021, 09:17:00 AM

Struggling US Retailers Owe $52 Billion in Overdue Rent

The coronavirus pandemic has turned consumerism right on its head with its strict social distancing...

Thursday, November 26, 2020, 10:30:00 AM

Kontrol Energy Announces HVAC Integration For BioCloud, Product Demonstrations In UAE

Kontrol Energy Corp (CSE: KNR) this morning had a minor update in relation to its...

Friday, December 11, 2020, 07:58:57 AM

Canadian Restaurant and Bar Sales Fall by Most on Record in 2020

The Covid-19 pandemic created significant negative impacts for a number of Canada’s economic sectors, causing...

Friday, February 19, 2021, 02:37:00 PM

Bill Morneau Details Justin Trudeau’s Lack of Fiscal Prudence During Covid-19 in New Book

Bill Morneau has re-entered the spotlight, this time to unravel the rifts he had with...

Tuesday, January 17, 2023, 06:21:00 AM